



[14 mai 2009 05:05 PM Europe / Heure d'été \(Paris, Rome, Berlin, Francfort\)](#)

## **Biosystems International SAS Initiates Development of a Diagnostic Blood Test for Lung Cancer**

PARIS--([BUSINESS WIRE](#))--Biosystems International a biotechnology company focused on the development of novel monoclonal antibody-based cancer diagnostics has initiated the development of an in vitro diagnostic blood test for lung cancer. This decision is based on the successful validation of a panel of monoclonal antibodies on multiple cohorts of lung cancer patients and control subjects.

The antibodies of the test under development were discovered using BSI's patented monoclonal antibody proteomics platform which has delivered a panel of lung cancer specific antibodies that has been tested on 4 patient cohorts totaling 367 patients and 304 controls and demonstrates > 80% sensitivity and > 80% specificity (for comparison, the PSA test for prostate cancer screening has a sensitivity of 35% and specificity of 63%). Importantly, similar values were obtained on a subpopulation of 128 patients with stage I cancer, demonstrating the strong potential to develop the first blood test to detect early stage lung cancer when it is treatable by surgery resulting in a dramatic increase in the chance for survival. Furthermore, a subset of antibodies discriminates between different histological subtypes, a finding which can aid in accurate diagnosis assuring appropriate treatment.

To confirm the specificity of the antibody panel to lung cancer, it has also been tested on control cohorts including subjects with non-malignant lung pathologies such as COPD, bronchial pneumonia, and fibrosis, as well as lung tumors of non-pulmonary origin. In all cases the antibodies were insensitive to these conditions as well as gender, treatment and smoking status.

### **About Lung Cancer**

Lung cancer is the most common form of cancer in men and women in Europe and the US with 365,000 new cases in Europe in 2006 and 215,000 in the US in 2008. Mortality from lung cancer is very high accounting for up to 30% of all cancer deaths. Because there are no screening methods for lung cancer, the disease is usually detected late when symptoms become apparent leading to an average 5 year survival rate of only 15%. However, early detection and surgery can be curative leading to an overall 5 year survival rate of up to 70% for patients with stage I cancer. Sadly, only about 15% of lung cancers are detected at the stage where surgical intervention is still possible.

JeanPierre Tirouflet, Biosystems International CEO stated:" A simple non-invasive blood test for the early detection of lung cancer has the potential to dramatically

increase the survival rate, saving many lives and significantly lowering the financial burden to society.”

### **About Biosystems International**

Biosystems International (BSI) is a biotechnology company aiming to become a world leader in the discovery and development of novel diagnostics for diseases with critical unmet needs. Using our proprietary monoclonal antibody proteomics process BSI rapidly discovers novel biomarkers and corresponding antibodies in a single step. The company is currently focused on the discovery and development of diagnostic tests in the areas of cancer and metabolic diseases as well as the development and commercialization of antibody arrays for plasma proteome profiling.

### **Safe Harbor Statement**

Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the company assumes no responsibility to update any such forward looking statements.

**Website:** <http://www.biosys-intl.com/>

### **Contacts**

#### **Biosystems International**

William Hempel, Director of Scientific Communications

+ 33 (0)1 60 87 89 75

[info@biosys-intl.com](mailto:info@biosys-intl.com)

**Permalien:** <http://www.businesswire.com/news/home/20090514005792/en>